Several THRβ-selective agonists have been developed recently36–38, and one such molecule, MGL-3196, is currently under phase 3 trials for the treatment of non-alcoholic steatohepatitis (NASH) and NAFLD39. This evidence concerns the gene THRB and metabolic dysfunction-associated steatohepatitis.